Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors

Author： Cascinu Stefano   Graziano Francesco   Catalano Vincenzo   Staccioli Maria   Barni Sandro   Giordani Paolo   Cristina Rossi Maria   Baldelli Anna   Muretto Pietro   Valenti Andrea   Catalano Giuseppina  

Publisher： Springer Publishing Company

ISSN： 0262-0898

Source： Clinical and Experimental Metastasis, Vol.18, Iss.8, 2000-12, pp. : 651-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 8, 2010-10 ,pp. : 593-600

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma

By Meister B.   Grunebach   Bautz F.   Brugger W.   Fink F.-M.   Kanz L.   Mohle R.  

European Journal of Cancer, Vol. 35, Iss. 3, 1999-03 ,pp. : 445-449

Elsevier

Access to resources Recommend Favorite

Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, Iss. 2, 2003-03 ,pp. : 95-117

Bentham Science Publishers

Access to resources Recommend Favorite

Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC)

By Oshika Y.   Nakamura M.   Tokunaga T.   Ohnishi Y.   Abe Y.   Tsuchida T.   Tomii Y.   Kijima H.   Yamazaki H.   Ozeki Y.   Tamaoki N.   Ueyama Y.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2390-2396

Elsevier

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite